5 citations
,
March 2025 in “Pediatric Dermatology” Alopecia areata in children is caused by the immune system attacking hair follicles due to genetic factors.
2 citations
,
February 2023 in “Vaccines” Some people experienced hair loss after COVID-19 vaccination, but it's very rare and vaccines' benefits are greater than this risk.
2 citations
,
July 2022 in “Cell Regeneration” Understanding hair growth involves complex factors, and more research is needed to improve treatments for hair loss conditions.
1 citations
,
March 2025 in “Skin Appendage Disorders” Healthcare access for alopecia areata in the USA is unequal among ethnic groups.
1 citations
,
February 2025 in “Medicina” No significant genetic link to alopecia areata was found in the Jordanian group.
1 citations
,
August 2023 in “Advanced Drug Delivery Reviews” Microneedles are promising for long-acting drug delivery and can improve patient compliance, but more data is needed to confirm their effectiveness.
April 2026 in “Frontiers in Immunology” Certain genes may be linked to autoimmune conditions in people with alopecia areata.
March 2026 in “Skin Appendage Disorders” Belatacept may be a promising treatment for alopecia areata.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
July 2025 in “Cell & Bioscience” Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.
June 2025 in “Journal of Cluster Science” Metal nanoparticles show promise for treating hair loss but need more research to ensure safety.
April 2025 in “Pharmaceutics” Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.
December 2024 in “Quality in Sport” PCOS involves immune system issues and inflammation, possibly leading to autoimmune diseases.
May 2024 in “International journal of medicine and psychology.” Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.
19 citations
,
July 1997 in “British Journal of Dermatology” LHTric-1 is a specific antibody useful for studying hair and nail formation.
7 citations
,
February 2012 in “British Journal of Dermatology” TH antibodies in vitiligo and AA patients recognize the same protein parts.
38 citations
,
January 2016 in “Cell Death and Disease” The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
April 2023 in “Journal of Investigative Dermatology” Trichohyalin in hair can trigger immune attacks in alopecia areata.
14 citations
,
August 2015 in “Endocrinology” The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.
August 1994 in “American Journal of Veterinary Research” Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.
April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
3 citations
,
October 1994 in “Journal of Dermatological Science” The new antibody, TYHF-1, specifically targets certain hair-related structures.
1 citations
,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.
November 2024 in “Malaysian Journal of Microbiology” Patients with thyroid disorders show different symptoms and antibody levels.
5 citations
,
June 2015 in “The Journal of Dermatology” HTLV-1-associated lichenoid dermatitis (HALD) is linked to an immune response against HTLV-1-infected cells.
1 citations
,
May 2023 in “The Journal of Immunology” CD4 T cells can cause alopecia areata by activating CD8 T cells to attack hair follicles.